Assessing the diagnostic impact of P63, PSA and BCL-2 proteins in premalignant and malignant prostate tissues


  • Aderonke C. Ogunlayi Department of Medical Laboratory Science, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Ekiti State, Nigeria
  • Victor O. Ekundina Department of Medical Laboratory Science, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Ekiti State, Nigeria
  • Adedapo O. Kehinde Department of Medical Laboratory Science, College of Basic Medical Sciences, Achievers University, Idasen-owo, Ondo State, Nigeria
  • Linus A. Enye Department of Anatomy Science, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Ekiti State, Nigeria
  • Adegoke O. Aremu Department of Medical Laboratory Science, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Ekiti State, Nigeria



Prostrate cancer, BPH, immunohistochemistry, PSA, P63, BCL-2, MPR


Background: Prostate cancer (CaP) is increasingly becoming a major health issue affecting men as cancer-related fatalities are attributable to the condition. Immunohistochemistry (IHC) diagnostic criteria can help in gene-targeted therapy and help reduce its prevalence. This study is to assess the diagnostic impact of prostate-specific antigen (PSA), P63 and BCL-2 antibodies in CaP.

Method: A case-controlled retrospective study was carried out on eighty (80) prostrate tissue blocks retrieved from the pathology archive of Ekiti State university teaching hospital Ado Ekiti. IHC analysis of the selected antibodies was carried out and also stained with haematoxylin and eosin (H and E) for second opinion and confirmation.

Results: The study showed that all the CaP samples had 100% positivity with varying reactivity to the IHC biomarkers; PSA had 100% positivity and MPR of 94% due to its multiple weaknesses as a biomarker p63 is a basal cells marker.

Conclusions: The expressions of these antibodies were observed in the progression of CaP. Although these markers are useful in predicting the progression from benign prostatic hyperplasia (BPH) to CaP, none of them can be utilised in isolation to a conclusion. Hence, they should be used in conjunction with one another to make up for their limitations. The immunohistochemical markers are beneficial in CaP diagnosis.


Metrics Loading ...


Rawla P. Epidemiology of Prostate Cancer. World Journal of Oncol. 2019;10(2):63-89.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clinicians. 2018;68(6):394-424.

Oh WJ, Chung AM, Kim JS, Han JH, Hong SH, Lee JY, Choi YJ. Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma. J Pathol Translational Med. 2016;50(5):345-54.

Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK, et al. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124(13):2801-14.

Mino-Kenudson M. Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. Translational Lung Cancer Res. 2017;6(5):570-87.

Khoury JD, Wang WL, Prieto VG, Medeiros LJ, Kalhor N, Hameed M, et al. Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. Clin Cancer Res. 2018;24(3):521-31.

De Matos LL, Trufelli DC, De Matos MGL, Da Silva Pinhal MA. Immunohistochemistry as an Important Tool in Biomarkers Detection and Clinical Practice. Biomarker Insights. 2010;5:9-20.

Kachuri L, Hoffmann TJ, Jiang Y, Berndt SI, Shelley JP, Schaffer KR, et al. Genetically adjusted PSA levels for prostate cancer screening. Nature Med. 2023;29(6):1412-23.

Egevad L, Delahunt B, Furusato B, Tsuzuki T, Yaxley J, Samaratunga H. Benign mimics of prostate cancer. Pathology. 2021;53(1):26-35.

Botezatu A, Iancu IV, Popa O, Plesa A, Manda D, Huica I, et al. Mechanisms of Oncogene Activation. In New Aspects in Molecular and Cellular Mechanisms of Human Carcinogenesis. InTech. 2016.

Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immuno-histochemistry analysis results in the bone tissue-a review. Diagnostic Pathol. 2014;9(1):221.

Alshahmi E, Obida E, Emaetig F, Elgaraboli F, Alqawi O. The Expression Profile of BCL-2 Protein in Prostate Cancer. Clin Oncol. 2021;6:1-5.

Pataky MW, Young WF, Nair KS. Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications. Mayo Clin Proceedings. 2021;96(3):788-814.

Liu YF, Shu X, Qiao XF, Ai GY, Liu L, Liao J, et al. Radiomics-Based Machine Learning Models for Predicting P504s/P63 Immunohistochemical Expression: A Noninvasive Diagnostic Tool for Prostate Cancer. Frontiers in Oncol. 2022;12:911426.

Ben-Jemaa A, Bouraoui Y, Sallami S, Banasr A, Rais NB, Ouertani L, et al. Co-expression and impact of prostate-specific membrane antigen and prostate specific antigen in prostatic pathologies. J Experimental Clin Cancer Res. 2010;29(1):171.

Van der Heul-Nieuwenhuijsen L, Hendriksen PJM, Van der Kwast TH, Jenster G. Gene expression profiling of the human prostate zones. BJU International. 2006;98(4):886-97.

Bonk S, Kluth M, Hube-Magg C, Polonski A, Soekeland G, Makropidi-Fraune G, et al. Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. Oncotarget. 2019;10(52):5439-53.

Leal J, Welton NJ, Martin RM, Donovan J, Hamdy F, Neal D, et al. Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. Cancer Epidemiol. 2018;52:99-105.

Nielsen MM, Tolbod LP, Borre M, Høyer S, Harms HJ, Sørensen J, et al. The relationship between tumor aggressiveness and cholinergic PET imaging in prostate cancer tissue. A proof-of-concept study. Am J Nuclear Med Molecular Imaging. 2019;9(3):185-92.

Kalantari MR, Anvari K, Jabbari H, Tabrizi FV. p63 is more sensitive and specific than 34βE12 to differentiate adenocarcinoma of prostate from cancer mimickers. Iran J Basic Med Sci. 2014;17(7):497-501.

Tan HL, Haffner MC, Esopi DM, Vaghasia AM, Giannico GA, Ross HM, et al. Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Modern Pathol. 2015;28(3):446-56.

Herawi M, Epstein JI. Immunohistochemical Antibody Cocktail Staining (p63/HMWCK/ AMACR) of Ductal Adenocarcinoma and Gleason Pattern 4 Cribriform and Noncribriform Acinar Adenocarcinomas of the Prostate. Am J Surgical Pathol. 2007;31(6):889-94.

Wu A, Kunju LP. Prostate Cancer with Aberrant Diffuse p63 Expression: Report of a Case and Review of the Literature and Morphologic Mimics. Arch Pathol Laboratory Med. 2013;137(9):1179-84.

Steurer S, Riemann C, Büscheck F, Luebke AM, Kluth M, Hube-Magg C, et al. p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. Biomarker Res. 2021;9(1):7.

Ma D, Zhou Z, Yang B, He Q, Zhang XH. Association of molecular biomarkers expression with biochemical recurrence in prostate cancer through tissue microarray immunostaining. Oncol Letters. 2015;10(4):2185-91.

Ozekinci S, Uzunlar AK, Senturk S, Gedik A, Buyukbayram H, Mizrak B. Expression of E-Cadherin, Cox-2, P53 and BCL-2 in Prostate Carcinomas: Correlation with Tumor Differentiation and Metastatic Potential. Biotechnol Biotechnological Equip. 2010;24(4):2112-6.

Eom YH, Kim HS, Lee A, Song BJ, Chae BJ. BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer. J Breast Cancer. 2016;19(3):252.

Patil T, Bernard B. Complications of Androgen Deprivation Therapy in Men with Prostate Cancer. Oncology (Williston Park, N.Y.). 2018;32(9):470-74.

Bhowal A, Majumder S, Ghosh S, Basu S, Sen D, Roychowdhury S, et al. Pathway-based expression profiling of benign prostatic hyperplasia and prostate cancer delineates an immunophilin molecule associated with cancer progression. Scientific Rep. 2017;7(1):9763.

Li F, Pascal LE, Zhou J, Zhou Y, Wang K, Parwani AV, et al. BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affected by finasteride and/or celecoxib. Am J Clin Experim Urol. 2018;6(1):1-10.






Original Research Articles